Please login to the form below

Not currently logged in
Email:
Password:

Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company

Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  

She joined the company in 2009 as VP of business development and, since 2011, had served as senior vice president and chief business officer and sat on Zealand's executive management team.  

David Solomon, Zealand's president and CEO, said: “Arvind Hundal has made valuable contributions to building Zealand's large portfolio of partnership agreements over the past five years.  

“It is to a large extent also thanks to Arvind and the team's achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavours.”  

Before joining Zealand Dr Hundal, who has over 20 years of experience in the life sciences sector, served as a member of AstraZeneca's strategic planning business development organisation and as business development director at Danish biotech 7TM Pharma.

15th December 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics